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S
peakers at the Fourth ResearchWorkshop on Alopecia
Areata clearly presented the state of current knowledge
in three fundamental areas of alopecia areata (AA) re-
search: genetics; immunology; and targets, triggers,
and controls. The ¢nal speakers reviewed what we
know about the treatment of AA and about the prospects for
treatment modalities in the future. It is clear that research related
to hair biology in general and AA in particular is now ¢rmly
established and expanding into important areas of fundamental
biology, including stem cell research and sophisticated studies of
epidermal di¡erentiation and morphogenesis. That the mechan-
ism of hair follicle dysfunction in AA is immunological, con-
trolled by activated T cells, is evident. Whether this response is
truly autoimmune remains to be ¢rmly established, but there
are strong indications that self antigens, including melanocyte
antigens, are the key targets. Susceptibility to AA is likely to be
genetically determined. Linkage to genes controlling the im-
mune response is strongest in patients with severe alopecia totalist
(AT) and alopecia universalis (AU), and it is probable that AA is a
polygenic complex trait, with distinct genetic linkages determin-
ing speci¢c gene subsets. Our understanding of the mechanisms
through which the cycling hair follicle is damaged and dysfunc-
tional in AAwas thoroughly reviewed in this conference.
HOWCLOSE AREWE TO SOLVING THE PUZZLE?
In spite of the progress reported here, we have a long way to go
before we completely understand the mechanisms of disease and
can identifyAA-speci¢c targets for treatment. On the other hand,
we may be very close to providing better treatment approaches.
Treatments proved to be e¡ective in other autoimmune skin dis-
eases can be used in AA in ‘‘proof of concept’’ trials, which will
both verify mechanisms of disease and provide practical ap-
proaches for treatment. Because AA is likely to be a complex ge-
netic trait, an understanding of the complexities of polygenic
interactions is necessary to grasp how genetic analysis should pro-
ceed. Fred Nijhout from Duke University presented an elegant
perspective on complex genetic interactions, using models devel-
oped in Drosophila to study the nature of robustness and genetic
mechanisms. Complex traits do not follow Mendel’s laws, the
correlations are often not linear, and there are complex networks
of interaction that can be mathematically modeled. Even within
these networks, however, there may be £at planes of response in
which linearity exists. The e¡ect of individual genes in such
models depends entirely on context. The summation of proper-
ties law states that the sum of the squares of the e¡ects of all genes
in a pathway is one; thus, identi¢cation of a gene with a major
e¡ect means that the e¡ects of other genes in the pathway may
be low. If, for example, we identify an immune response gene
that is necessary for the development of AA, then the other genes
in the pathway may be of rather minor importance and only
some of them may be necessary for expression of disease. More-
over, certain genes may determine which subsets of disease, such
as AA, AU, or AT, may occur. The importance of context is clear
in the hair follicle, where cross-talk among di¡erent cell popula-
tions controls follicle cycling. This point was made repeatedly in
many of the presentations here, especially in the elegant presenta-
tion by Elaine Fuchs on the control of epidermal and follicular
di¡erentiation.
Richard Kalish presented a summary of data that he and Amos
Gilhar have produced over the past ten years, demonstrating that
AA is an autoimmune disease mediated by T lymphocytes in
which autoantiogens are necessary to activate T cells that produce
the disease. The model they used is a SCID mouse (de¢cient in
the ability to respond to human skin grafts) engrafted with hair-
bearing human skin. Leukocytes from AA patients were stimu-
lated in vitro with hair follicle antigens and injected into these
engrafted mice. The result was immunologic hair loss like that
seen in AA. Similar SCID mouse models have been e¡ectively
used to study autoimmune skin disease in psoriasis and photosen-
sitive lupus, but the Kalish/Gilhar model is particularly useful
and robust. With it, Kalish and Gilhar showed that cells from
AA patients, activated by hair follicle antigens, can transfer AA.
In this adoptive transfer model, both CD4þ and CD8þ T cells
are necessary for maximal e¡ect, even though CD8þ cells alone
are su⁄cient to induce hair loss. More recently, the two research-
ers showed that hair follicle antigens as a requirement to stimulate
T cells in this transfer model can be replaced by follicular mela-
nocytes. This provides evidence that follicular melanocytes may
be the targets for activated T cells in AA, as originally proposed
by Tobin and Bystryn. It is interesting that control of certain
melanocytic peptides is linked to immune response major histo-
compatibility complex (MHC) loci, providing another possible
point of control of AA by the MHC.
Jerry Niederkorn provided some new perspectives on how
certain locations in the body, such as the eye, might have very
unique immunologic environments. This is a concept developed by
his mentor,Wayne Streilein. The eye is a unique structure charac-
terized by ‘‘immune privilege,’’ that is, the resistance to induction
of acquired immunity in that site. This resistance to immune re-
sponse is based on a number of mechanisms: lack of lymphatic
drainage, anterior chamber immune deviation, immunosuppres-
sive e¡ects of the aqueous humor itself, low MHC expression,
low expression of Langerhans cells or antigen-presenting cells,
and inhibition of natural killer cells. Niederkorn proposed the
idea that immune privilege in the hair follicle also protects the
key structures of the follicle, such as stem cells in the bulb, from
immune destruction.
Ralf Paus is the father of the concept of immune privilege in
the hair follicle. MHC class I molecules are not expressed in the
hair matrix, in the dermal papilla, or in the outer root closest to
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the bulb. They are necessary in initiating immune responses
in which endogenous antigens are presented to activate CD8þ
T lymphocytes.
INF-g generated by activated T lymphocytes and natural killer
cells can upregulate class I expression. In the hair follicle, such
expression may be inhibited locally by growth factors, such as
a-MSH, TGF-b, and IGF-1, acting in this instance as immuno-
modulating molecules. But Paus proposes that it is inhibited lo-
cally by a number of growth factors acting through the receptors,
which in this sense act as immunomodulating chemicals.
It may be that the purpose of immune privilege in the hair
follicle is indeed to protect the follicle’s stem cells. I propose an
alternative explanation: that the lack of MHC class I expression
in the lower regions of the hair follicle is intended to protect the
follicle from induction of autoimmunity during regression of the
catagen follicle. In regression of the catagen follicle, the epithelial
cells and melanocytes of the matrix, and the epithelial cells of the
root sheaths nearest the hair bulb, all undergo apoptosis. Apopto-
tic fragments of the cells are available for ingestion by cells lo-
cally. If those cells had class I expression, could internalize those
antigens, and present them on the surface in the context of class I
that would induce an immune response against self antigens. The
hair follicle is unique in that it repeatedly undergoes cycles of cell
death and then regrowth, continually leaving apoptotic materials
within the dermis. The di¡erentiating epidermis, on the other
hand, disposes of apoptotic corneocytes by desquamation.
In this context, Paus proposes an ‘‘immune privilege collapse
model’’ to explain the development of autoimmunity in AA.
In this model, infections, bacterial superantigens, or follicular
damage trigger release of INF-g, which induces expression of
class I MHC on follicular cells leading to induction of CD8þ
cytotoxic cells and also of class II MHC molecules, leading to
induction of CD4þ help and then to downstream autoimmune
phenomenon. Downstream from all of this is a spread of the
immune response with antibody, macrophagus, expression of
Fas Ligand, apoptosis, and damage to follicular cells. Is there a
genetic predisposition to the breakdown of immune privilege in
AA? I believe that is clearly one area of hair biology research that
requires additional funding.
David Duggan provided a clear review of how gene arrays
might be generally applied to the study of gene expression in
cancer and in£ammatory diseases. Several speakers presented their
work on the application of microarray technology to the study of
AA in human and animal models. I was impressed with Jerry
Shapiro’s studies using microarray and proteomic analysis to look
at gene and protein expression patterns in response to therapy in
the rat AA model. Another important approach is that reported
by John Sundberg, using C3H/HeJ mice to study genes that are
turned on in induction of AA. In both of these approaches, mi-
croarray changes are studied in the context of turning on or turn-
ing o¡ AA. Initial studies by Sinha of microarray analysis in
human AA have shown predictable changes in keratins and cyto-
kines. David Duggan made a case for application of microarray
technology to human AA, but we should be wary in the choice
of experimental approach. I would favor using microarrays as
they have been applied in animal models of AA, looking at ex-
perimental situations where AA is turned on or o¡that is, at
AA in transition, not just in established disease.
C3H/HeJ mice develop spontaneous AA-like disease in about
20% of cases and will predictably develop multiple sites of alope-
cia if involved skin is grafted onto uninvolved mice. This allows
the development of large populations of alopecia mice with active
progressing disease, which is an ideal model for gene and protein
expression studies. Using microarray analysis, Sundberg found a
decrease in genes controlling pigment and hair proteins early in
the disease, which is just what we would expect. As the hair fol-
licles are involuting, he found, IFN-g, antigen-presenting cells,
and, later, induction of antibodies of multiple speci¢cities in-
crease. The changes in antigen-presenting cells may be an impor-
tant determinant of the development of autoimmunity. The
C3H/HeJ animal model, which has the capacity for induction of
disease by the grafting of AA-a¡ected skin, may be perfect for
the study of immune privilege breakdown in AA and for the
study of T cell responses in the disease.
Epitope spreading is the expansion of the speci¢cities of an
immune response with time, characterized by the spreading of
the immune response to recognize more epitopes on the same
protein or epitopes similar to the one that initiated the immune
response. An epitope is a small polypeptide fragment recognized
by antibodies or T cell receptors. The C3H/HeJ mouse model is
the place to begin looking for epitope spreading, for T cell recep-
tor repertoire, and for speci¢c receptors and what antigens they
recognize, using the inducible aspect of the model to study early
and later immune responses. The genetic associations in the mod-
el show strong linkage to chromosome 17: DQB1, DRB1, TNF,
and LT, and to chromosome 9: CD3 NCAM. These are clearly
regions that control the immune response and provide some idea
of the genetic loci that will be identi¢ed in human AA.
Madeleine Duvic presented an update on the National AA
Registry. This registry will provide the means for collection of
data on disease subsets and natural history. In addition, it will
focus on collection of multiplex families and sib pairs, which will
be important in the study of genetic linkages in AA, AT, and AU.
The power of genetic approaches was addressed by Angela
Christiano. She reported on the results of a study of ¢ve large
multiplex families with AA, using some families not enrolled in
the registry. Her initial results show signi¢cant linkages at four
sites: chromosomes 10, 6, 16, and 18. So, we are starting down the
road of ¢nding the genes responsible for this disease.
Elaine Fuchs discussed theWNTsignaling pathway and how it
controls cell proliferation, transcription, and adhesion and attach-
ment.WNT signaling is important in stem cell development, in
hair follicle determination, and in the commitment of hair
matrix cells to formation of hair keratins. The details of how the
signaling pathways link cell attachment, proliferation, and di¡er-
entiation will provide fundamental understanding of the molecu-
lar control of hair follicle development and cycling. In the
context of AA, this knowledge may make it possible to maintain
follicle growth even in the face of immune attacks.
Another crucial signaling pathway controlling hair follicle
development is Sonic Hedgehog (SHH), discussed by Andrzej
Dlugoz. SHH is required for hair follicle growth but not for
di¡erentiation, and mutations in this pathway produce basal cell
carcinoma (BCC). Downstream mutations stop hair follicle
regression and induce tumors like BCC. We are developing a
fundamental understanding of control of the development and
cycling of hair follicles involving multiple signaling elements
and growth factors: WNT and Sonic Hedgehog, keratinocyte
growth factor, ¢broblast growth factor-V, and NOGGIN.
It is clear that neuropeptides are involved in controlling the
immune response in psoriasis and atopic dermatitis. Vladimir
Botchkarev proposed that they may control CD8þ lymphocyte
populations in AA as well. His evidence is compelling that neu-
rotrophins are present in the hair follicles in AA lesions and that
they can kill peripheral blood CD8þ T cells from AA patients.
Do neurotrophins eliminate CD8þ suppressors intended to
terminate the immune response? DavidWhiting showed us that
T cells are eliminated from lesions of long-established AA. Are
neurotrophins the mechanism for their disappearance? We need
new studies to determine what stimulates T lymphocytes in AA
and what makes them disappear in long-standing lesions.
Kevin McElwee presented additional work showing how
valuable the C3H/HeJ mice model can be. Grafting involved
skin from one mouse onto syngeneic mice without AA leads to
progressive AA development. In these induced mice, there are
complex immunologic changes: in£ammatory in¢ltrates consist-
ing of CD4þ4CD8þ lymphocytes, macrophage, and B cells;
local increase in cytokines IL-12, IL-64IL-10, and IL-4; all T cell
subsets, including T regulatory cells; and hair follicle changes re-
quiring Fas and FasL. The speci¢c role of T cell cytokines in
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inducing apoptosis in the follicle in AAwill be an area of active
investigation.
Desmond Tobin has persisted in his quest to identify antibo-
dies in di¡erent AA modelshuman, mouse, horse, chicken,
and others. In human AA, there are high-titer antibodies to hair
follicle antigen, sometimes as high as 1:10,000; in the rat model
they precede hair loss. If melanocytes are grown from hair folli-
cles, these antibodies bind to them and the binding can be nucle-
ar, cytoplasmic, and membrane. In multiple animal models, there
are also antibodies to keratin or trichohyalin. E¡ective treatment
of AA decreases the antibody levels, which I think is further evi-
dence for a complex immune response. These antibodies can also
be used as tools to determine immunologic speci¢city as they can
be easily sampled and antibody speci¢cities can be more easily
measured than with T cell speci¢cities. I believe this is going to
be a useful way to look at epitope spreading and maturation of
the immune response in AA. It was recently shown that immu-
notherpy in melanoma treatment can induce regression of both
melanoma and vitiligo.The melanocyte destruction in these areas
of AA appears to be mediated by autoantibodies, reawakening
our interest in antibody destruction of melanocytes.
Jerry Shapiro showed that modern gene expression techniques
can be used in animal models to determine the mechanism of ac-
tion of the established treatment approaches of topical anthralin
and nitrogen mustard. Anthralin induced hair regrowth in the rat
alopecia model and decreased interferon-g and thymosin and
JNK signaling. Topical nitrogen mustard also decreased INF-g,
and increased IGF-1.These studies validate INF-g as an important
mediate in AA and suggest that other signaling pathways may be
necessary for re-emergence of new hair follicles.
JonathanVogel presented an interesting view of the future and
how gene creams or solutions or the injection of DNA can be
used to modify skin function and may be directed to treat hair
disorders such as AA. Even better, hair follicles may be removed,
transduced ex vivo, and then transplanted to AA patches.Will gene
therapy make AA a surgical disease?
Amy McMichael and Vera Price presented their views on the
new immunomodulators developed for the treatment of psoriasis
and now available to test for AA. These therapies fall into four
major categories: killing activated T cells, inhibiting T cell activa-
tion, inducing immune deviation, and inhibiting key cytokines.
The prototype drug for killing activated Tcells is Ontak, a fusion
protein containing a toxin and an anti-IL-2R antibody. Drugs
that block T cell activation interfere with macrophage^T cell
interactions by binding the TCR or secondary adhesion and
signaling pairs. Immune deviation drugs switch the T cell re-
sponse from TH1 to TH2. Cytokine-inhibiting drugs interfere
with cytokines, such as TNF-a, or their receptors (Enbrel
and Remicaide). Another important approach in development is
interference with leukocyte tra⁄cking through the binding of
important adhesion structures such as ICAM-1 and selectins.
The presentations at this Fourth International Alopecia Areata
Workshop taught us about the current state of research on AA
and hair biology and related topics in cutaneous biology. I think
that it is also important that we learn from others who have stu-
died cutaneous autoimmune diseases and that we discover how to
apply some of the lessons from these diseases to a better under-
standing of AA.
Lupus erythematosus is the prototypical autoimmune disease,
and there is much to learn from it. John Harley just presented,
at the Montagna Symposium on the Biology of Skin (2002), the
results of an 8-year study of the genetics of lupus, in which he
found that many of the genetic associations could be identi¢ed
only by study of carefully segregated subsets of disease based on
organ involvement, autoantibody speci¢city, and clinical features
(Harley 2002; Kelly, 2002). In implementing the Alopecia Areata
Registry, we must take care to collect similar clinical data related
to AA subsets.
Vicky Werth has studied the susceptibility to photosensitivity
in cutaneous lupus, focusing on polymorphisms in genes asso-
ciated with immune response and cell death, speci¢cally TNF-a
(Werth, 2000). This is a key mediator in in£ammation in the skin
and in control of cell death. It is believed that these TNF poly-
morphisms may be important in the UV-induced cell death that
leads to autoantibody production in photosensitive lupus. Poly-
morphisms in TNF, IL-1, and other MHC-associated molecules
will be important in studies of AA biology and genetics.
Landmark work done over the past six or seven years by Livia
Casciola-Rosen and Anthony Rosen at Johns Hopkins has shown
that many autoimmune diseases are produced by autoantibodies
speci¢c for fragments of self antigens produced during apopto-
sis and presented to a defective immune system (Rosen, 1999;
Rosen, 2001). The prototype of this mechanism is photosensitive
lupus, in which UVR-induced apoptosis induces fragments of
r antigens (Casciola-Rosen, 1996). Apoptosis is the principle me-
chanism of cell death in the regressing catagen follicle, and it may
be that these apoptotic cellshair matrix melanocytes, matrix
keratinocytes, and root sheath keratinocytesare being presented
to the immune response and that autoimmunity develops in AA
because of genetically determined immune response defects. Is
the immune response in AA directed against proteolytic frag-
ments of autoantigens exposed during catagen? Is the principal
genetic defect in AA related to how the cells of the hair follicle
die during catagen?
Psoriasis provides many possible lessons for those studying
AA. It is a T cell-dependent disease, often triggered by infection.
What is most unique about psoriasis is that carefully planned
clinical trials were used to understand the mechanisms of disease
(Gottlieb, 1995, Krueger, 2002). The model was simple and direct:
Employ a highly speci¢c treatment modality that targets a single
point in the mechanism you are evaluating. Jim Krueger and
Alice Gottlieb used highly selective anti-T cell treatments to
reverse intractable psoriasis. Those that killed activated T cells
(Ontak, UVR) led to remission of disease, whereas those that
merely inhibited Tcell activation (cyclosporine) produced clinical
response but no remission when treatment was discontinued.
In AA, we must determine if killing T cells will also allow
return of normal hair follicle function. If AA is triggered by an
infection, will the immune response persist after the infection is
gone? If there is epitope spreading, will the disease persist if the
activated T cells are killed? Studies using speci¢c anti-T cell treat-
ments are essential to ¢nding answers to these questions. There
are a number of di¡erent models that we could use: drugs that
target pathogenicTcells, drugs that inhibit Tcell activation, drugs
that induce immune deviation toward TH2 cells, and drugs that
inhibit cytokines such as TNF-a. Killing pathogenic T cells is
probably the best treatment because it can be seen if a remission
is achieved when treatment is discontinued. Such drugs need to
be used in ‘‘proof of concept’’experiments.
Vitiligo is another autoimmune disease from which we can
learn many lessons. Also a complex autoimmune disease, it is
characterized by both autoreactive T cells and autoantibodies. In
vitiligo, repigmentation of a¡ected skin is a separate process that
involves more than just suppression of the immune response.
Repigmentation is distinct from pigment cell destruction (Norris,
1994), which requires activation of a special population of melano-
cyte precursors in the outer root sheath (Horikawa, 1996). In AA,
hair cycling returns when immunosuppressives are used, but not
in every patient. In the patients that do not respond to the block-
ing of the immune response, does something else have to be added
to directly stimulate the hair follicle? A better understanding of
follicle cycling and control will provide us the tools to answer
this question and perhaps to ¢nd stimuli for anagen growth that
overcome the inhibition imposed by the immune response in AA.
This workshop summarized the signi¢cant accomplishments
in understanding hair biology and AA achieved since the ¢rst
NIAMS-sponsored workshop.We have established that AA is a
Tcell-mediated disease and that it appears to be autoimmune. In-
vestigators have identi¢ed some of the antigens to which the im-
mune response is directed in AA, an accomplishment not yet
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achieved in psoriasis.We have had a tremendous growth in un-
derstanding of the biology of the follicle and its role as an im-
mune-privileged site. Moreover, we have initial genotyping of
immune response-associated genes, especially in AT and AU.We
are also identifying other genes, and we will continue to do that
as patient populations become larger. Through the National Alo-
pecia Areata Registry, we are collecting the patient data necessary
to understand the natural history and epidemiology of this
disease, and we are beginning to stratify patients by disease
subset, which is necessary for these studies and for the genetic
analyses now under way.We have begun to correlate the di¡erent
stages of pathology of the hair follicle with disease subset,
with biochemical markers of immune disease, with hair follicle
response, and with the complex genetic determinants of AA and
its subsets.
What needs to be done? We must continue to support basic
research in hair follicle biology as the foundation on which un-
derstanding of pathophysiology and treatment will be built, and
we need to support our Alopecia Areata Registry as the basis for
fundamental mechanism and treatment trials. We also need to
strongly support genetic studies if we are to understand disease
mechanism and disease subsets, and we need to fund opportu-
nities to apply new research approaches such as gene and protein
expression through microarray analysis and proteomics. I
strongly believe that we need to aggressively organize proof of
concept clinical trials to verify that activated T cells are essential
for development of AA and that anti-T cell drugs cause its rever-
sal.We have to study the return of hair growth after the immune
response is blocked to see if additional stimuli are needed to ‘‘re-
start’’ cycling. I think it is time to take our animal models and
develop the appropriate collaborations with fundamental T cell
biologists to determine theTcell receptor repertoire in the lesions
of AA.What are these cells recognizing? Is it the same patient to
patient? Is there epitope spreading? Does the T cell response cease
late in disease? Indeed, we are close to major breakthroughs in
understanding the mechanism and treatment of AA.
I must express sincere appreciation to NIAMS for their support
of this entire ¢eld over the past ten years, and I personally and
speci¢cally want to thank Alan Moshell, head of the Skin Pro-
gram at NIAMS, who in so many ways has helped to support the
investigators in their e¡orts to understand AA and hair biology
through these meetings, through publication of these proceedings
in the Journal of Investigative Dermatology, and through good advice
on funding approaches. Of course, I also should thank Steve
Katz, the director of NIAMS, for his support of the development
of this area of research.
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